Ceretas Ltd (ASX:CTS) Share Price & Analysis

Ceretas Limited (ASX: CTS) is an Australian clinical-stage medical technology company headquartered in Brisbane, Queensland. Listed on the Australian Securities Exchange under the ticker symbol CTS, the company is dedicated to the research, development, and commercialisation of innovative healthcare technologies. Its core focus lies in pioneering non-invasive therapeutic platforms designed to treat complex neurodegenerative disorders, with a primary concentration on Alzheimer’s disease.

The company’s technology portfolio centers on a portable, image-guided therapeutic ultrasound platform originally licensed from UniQuest, the commercialisation arm of the University of Queensland. Operating through low-intensity focused ultrasound, the platform delivers targeted neuromodulation at the neural circuit level and enables reversible blood-brain barrier opening using circulating microbubbles. This process facilitates the brain’s natural clearance of toxic amyloid-beta and tau proteins. Ceretas manages its clinical trial programs and research footprint across Australia from its Brisbane headquarters.

Ceretas targets the rapidly growing central nervous system therapeutic market, addressing significant unmet medical needs for millions of dementia and Alzheimer’s patients worldwide. The company’s strategic growth plan centers on progressing clinical trials toward regulatory approvals, advancing commercialisation pathways, and exploring secondary applications such as co-administered drug delivery across the blood-brain barrier. By offering scalable, non-invasive therapeutic options, Ceretas aims to provide substantial value to healthcare systems, clinicians, and patients globally.